Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure | Zendy

Xiangyu Zhang | Zendy; Yi Xiong | Zendy; Qing Xia | Zendy; Fang Wu | Zendy; Lingli Liu | Zendy; Yuling Zhou | Zendy; Liang Zeng | Zendy; Chunhua Zhou | Zendy; Xia Chen | Zendy; Wenjuan Jiang | Zendy; Dehua Liao | Zendy; Lili Xiao | Zendy; Li Liu | Zendy; Haiyan Yang | Zendy; Rui Guan | Zendy; Kunyan Li | Zendy; Jing Wang | Zendy; Guang Lei | Zendy; Yongchang Zhang | Zendy; g Yang | Zendy

Open Access

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure

Author(s) -

Xiangyu Zhang,

Yi Xiong,

Qing Xia,

Fang Wu,

Lingli Liu,

Yuling Zhou,

Liang Zeng,

Chunhua Zhou,

Xia Chen,

Wenjuan Jiang,

Dehua Liao,

Lili Xiao,

Li Liu,

Haiyan Yang,

Rui Guan,

Kunyan Li,

Jing Wang,

Guang Lei,

Yongchang Zhang,

g Yang

Publication year - 2020

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.1226

Subject(s) - vinorelbine , apatinib , medicine , lung cancer , clinical endpoint , oncology , adverse effect , chemotherapy , cancer , progressive disease , clinical trial , surgery , gastroenterology , cisplatin

This nonrandomized clinical trial examines the efficacy and safety of apatinib plus vinorelbine in patients in China with wild-type advanced non–small cell lung cancer (NCSLC) that was resistant to 2 or more lines of chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research